NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GentiBio

GentiBio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.gentibio.com/

Last Round

Series A

Aug 11, 2021

Total Funding Raised

$177M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GentiBio is a biotechnology company that develops engineered regulatory T-cell (EngTreg) therapies to restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regulatory T cellTregcell therapyengineered cell therapyimmune toleranceautoimmune disease treatmentbiotechnext-gen cell therapyantigen-specific Tregbiopharmaceutical partnershipautologous therapyallogeneic therapysynthetic biologydrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GentiBio Comparables

Compare GentiBio with similar companies based on industry and business-model similarity.

GentiBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Quell Therapeutics
87%
Sonoma Biotherapeutics
86%
Mozart Therapeutics
86%

GentiBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 11, 2021
SeedAug 5, 2020

Key People

Founding team and executive leadership

Andy Walker

Co-founder, President And Chief Executive Officer (CEO)

Founding Team

GentiBio Investors

Notable investors and investment history

GentiBio investors
InvestorRounds
RA Capital ManagementSeries A, Seed
Avidity PartnersSeries A
OrbiMedSeries A, Seed
Matrix Capital ManagementSeries A
JDRFSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2026

    Will present new data on engineered Treg therapy at the PES Annual Meeting.

  • Apr 29, 2026

    New data on GNTI-122 Treg therapy to be presented at medical conference.

GentiBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GentiBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GentiBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range43
Year Founded2020
Last FundingAug 11, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.